EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, DARE:

06 Oct 25 19:34
LAST:

2.289

CHANGE:
 0.07		OPEN:
2.210		HIGH:
2.430		ASK:
2.000		VOLUME:
299.1K
CHG(%):
3.21		PREV:
2.180		LOW:
2.140		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
06 Oct 252.2302.2802.1502.250314.9K
03 Oct 252.1502.2102.1402.180112.4K
02 Oct 252.1602.1802.1052.15098.6K
01 Oct 252.1102.1702.1102.15090.9K
30 Sep 252.0802.1402.0802.10094.3K
29 Sep 252.0902.1402.0702.09077.4K
26 Sep 252.0702.1102.0502.090117.4K
25 Sep 252.1402.1402.0302.080158.7K
24 Sep 252.1002.1762.0802.140177.2K
23 Sep 252.0402.1002.0402.06077.3K

COMPANY PROFILE

Name:Dare Bioscience Inc
About:Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
Sector:Healthcare
Industry:Biotechnology
Address:3655 Nobel Drive, San Diego, CA, United States, 92122
Website:https://darebioscience.com
CUSIP:15708Q105
CIK:0001401914
ISIN:US23666P1012
FIGI:BBG001J2P362

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:2.17
MA10:2.13
MA20:2.11
MA50:2.14
MA100:2.46
MA200:2.75
STO9:85.00
STO14:87.50
RSI14:64.76
MTM14:0.20
ROC14:0.10
ATR:0.08
Week High:2.28
Week Low:2.07
Month High:2.28
Month Low:2.03
Year High:9.19
Year Low:1.83
Volatility:15.21

RECENT SPLITS

Date Ratio
01 Jul 20241-12
20 Jul 20171-10